GleamWall
中文EN

NRXP NRX Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1719406 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,076.5%
TTM net income YoY48.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin40.5%
Operating margin-551.7%
Net margin-454.1%
FCF margin—
EBITDA margin-546.4%

Returns

ROE—
ROA-92.3%
ROIC (approx.)—
Asset turnover0.20x

Leverage & solvency

Liabilities / assets107.1%
Debt / equity—
Current ratio0.76x
Interest coverage-17.37x

Cash quality & payout

Operating cash flow / net income1.19x
Accruals ratio17.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.23M$0
Cost of revenue$505,000$0
Gross profit$720,000$0
R&D expense$3.78M$6.20M
SG&A expense$13.06M$13.50M
Operating income-$16.22M-$18.50M
Interest expense$671,000$230,000
Income tax$0$0
Net income-$28.62M-$25.13M
EBITDA-$16.15M-$18.50M
EPS (basic)-1.34-2.36
EPS (diluted)——
Balance sheet
Cash & equivalents$7.80M$1.44M
Receivables$161,000$0
Current assets$8.89M$3.30M
PP&E, net$63,000$10,000
Goodwill$1.79M$0
Intangibles$925,000$0
Total assets$12.96M$3.65M
Current liabilities$28.58M$21.86M
Total liabilities$28.89M$26.87M
Shareholders' equity-$15.94M-$23.22M
Shares outstanding31.73M14.59M
Cash flow statement
Operating cash flow-$14.11M-$10.64M
Capital expenditure—$0
Free cash flow—-$10.64M
Investing cash flow-$2.81M$0
Financing cash flow$23.28M$7.49M
Depreciation & amortization$70,000$5,000
Stock-based compensation$228,000$486,000

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.